EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Bevacizumab-based chemotherapy adaptive to pharmacokinetic of bevacizumab in first-line treatment of patients with unresectable metastatic colorectal cancer: A double-blind, multicenter, randomized phase III trial study (PHARBEVACOL trial)

Thierry Lecomte, Bruno Giraudeau, Jean-Marc Phelip, Christophe Tournigand, Michel Ducreux, David Tougeron, Côme Lepage, Laurent Mineur, Philippe Laplaige, Romain Desgrippes, Pascal Artru, Christophe Borg und 15 weitere

Digestive and Liver Disease · 2025

DOI: 10.1016/j.dld.2025.02.002 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Digestive and Liver Disease, 2025. Verfasst von Thierry Lecomte und 26 weiteren Autor:innen. Beteiligte Einrichtung: Service d'Hépato-gastroentérologie et de cancérologie digestive, CHU de Tours, Tours, France; INSERM UMR 1069, N2COx "Niche, Nutrition, Cancer and Ox…. Hauptthemen laut MEDLINE: Antineoplastic Agents, Immunological, Antineoplastic Combined Chemotherapy Protocols, Bevacizumab, Colorectal Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Unicancer, Centre hospitalier régional universitaire de Lille, French National Cancer Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic Agents, ImmunologicalAntineoplastic Combined Chemotherapy ProtocolsBevacizumabColorectal NeoplasmsAdultAgedFemaleHumansMaleMiddle AgedDouble-Blind MethodProgression-Free SurvivalClinical Trials, Phase III as TopicMulticenter Studies as TopicRandomized Controlled Trials as Topic

Stichwörter der Autor:innen

BevacizumabMetastatic colorectal cancerPharmacokineticsTherapeutic drug monitoring

Substanzen

Antineoplastic Agents, ImmunologicalBevacizumab

Autor:innen und Institutionen

  • Service d'Hépato-gastroentérologie et de cancérologie digestive, CHU de Tours, Tours, France; INSERM UMR 1069, N2COx "Niche, Nutrition, Cancer and Oxidative Metabolism", Université de Tours, Tours, France. Electronic ad…
  • INSERM CIC1415, CHU de Tours, Tours, France.
  • Service d'Hépato-gastroentérologie et de cancérologie digestive, CHU Saint Etienne, Saint Etienne, France.
  • Service d'Oncologie Médicale, Hôpital Henri Mondor, AP-HP, UPEC, Créteil, France.
  • Service d'Oncologie digestive, Institut Gustave Roussy, Villejuif, France.
  • Service d'Hépato-gastroentérologie, CHU de Poitiers, Poitiers, France.

Förderung

  • Unicancer
  • Centre hospitalier régional universitaire de Lille
  • French National Cancer Institute

Zitieren

APA

Lecomte, T., Giraudeau, B., Phelip, J. M., Tournigand, C., Ducreux, M., Tougeron, D., Lepage, C., Mineur, L., Laplaige, P., Desgrippes, R., Artru, P., Borg, C., Jary, M., Bouché, O., Metges, J. P., Guimbaud, R., Aparicio, T., Foubert, F., Hautefeuille, V., …, & Ternant, D. (2025). Bevacizumab-based chemotherapy adaptive to pharmacokinetic of bevacizumab in first-line treatment of patients with unresectable metastatic colorectal cancer: A double-blind, multicenter, randomized phase III trial study (PHARBEVACOL trial). Digestive and Liver Disease. https://doi.org/10.1016/j.dld.2025.02.002

Vancouver

Lecomte T, Giraudeau B, Phelip JM, Tournigand C, Ducreux M, Tougeron D, et al. Bevacizumab-based chemotherapy adaptive to pharmacokinetic of bevacizumab in first-line treatment of patients with unresectable metastatic colorectal cancer: A double-blind, multicenter, randomized phase III trial study (PHARBEVACOL trial). Digestive and Liver Disease. 2025. doi:10.1016/j.dld.2025.02.002

BibTeX
@article{Lecomte2025,
  author = {Lecomte, Thierry and Giraudeau, Bruno and Phelip, Jean-Marc and Tournigand, Christophe and Ducreux, Michel and Tougeron, David and Lepage, Côme and Mineur, Laurent and Laplaige, Philippe and Desgrippes, Romain and Artru, Pascal and Borg, Christophe and Jary, Marine and Bouché, Olivier and Metges, Jean-Philippe and Guimbaud, Rosine and Aparicio, Thomas and Foubert, Fanny and Hautefeuille, Vincent and Muller, Marie and Bouhier-Leporrier, Karine and Darrius, Rémi and Lobet, Sarah and Monmousseau, Fanny and Bejan-Angoulvant, Théodora and Paintaud, Gilles and Ternant, David},
  title = {Bevacizumab-based chemotherapy adaptive to pharmacokinetic of bevacizumab in first-line treatment of patients with unresectable metastatic colorectal cancer: A double-blind, multicenter, randomized phase III trial study (PHARBEVACOL trial)},
  journal = {Digestive and Liver Disease},
  year = {2025},
  doi = {10.1016/j.dld.2025.02.002}
}
Kostenlos starten →